JBNB  Vol.4 No.3 , July 2013
Usefulness of Basic Fibroblast Growth Factor (bFGF) Loaded Dissolving Microneedles for Local Therapy of Skin Wounds
ABSTRACT
Purpose: The usefulness of dissolving microneedles (DMs) for local skin therapy by basic fibroblast growth factor (bFGF) was studied in rats. Methods: We prepared four kinds of bFGF-loaded DMs, approximately 500 μm length and 300 μm diameter at the bottom. Long-term stability and dissolution studies were performed by HPLC method. Pharmacokinetic and pharmacological evaluations were performed after administration of bFGF loaded DMs to rats. Results: The bFGF contents were 2.15 ± 0.07, 1.07 ± 0.04, 0.56 ± 0.07 and 0.12 ± 0.03 μg. The 100.2 ± 3.4%, 100.2 ± 3.3%, 99.3 ± 1.4% and 100.4 ± 3.0% of bFGF were recovered after 1, 3 and 6 months and 1 year incubation at 40°C. The bFGF was released from DMs within 5 min. In a pharmacokinetic study using 2.0 and 1.0 μg bFGF-loaded DMs, no systemic exposure of bFGF was detected. The initial bFGF concentrations in the rat skin tissue after administration of bFGF-loaded DMs to the hair-removed rat abdominal skin were 510.2 ± 20.1 ng/g wet weight for 2 μg bFGF DMs and 264.2 ± 56.5 ng/g wet weight for 1 μg DMs, declining slowly thereafter to 226.3 ± 33.5 and 105.1 ± 27.4 ng/g wet weight at 6 hr after administration. Good dose-dependency was observed. Pharmacological evaluation of bFGF-loaded DMs of 2.0, 1.0, 0.5, and 0.1 μg, in the wound healing rat model, all used DMs, but 0.1 μg DMs, showed good healing effects. Considered collectively, these results suggest the usefulness of bFGF-loaded DMs for local therapy of skin wound disease.

Cite this paper
K. Takada, Y. Ito, K. Matsumoto, Y. Sato, M. Nishio, Y. Tadano, Y. Kamei, Y. Takemura, N. Inoue, Y. Akasaka and I. Ono, "Usefulness of Basic Fibroblast Growth Factor (bFGF) Loaded Dissolving Microneedles for Local Therapy of Skin Wounds," Journal of Biomaterials and Nanobiotechnology, Vol. 4 No. 3, 2013, pp. 256-264. doi: 10.4236/jbnb.2013.43032.
References
[1]   K. Takada, “Microfabrication Derived DDS: From Batch to Individual Production,” Drug Discoveries and Therapeutics, Vol. 2, No. 3, 2008, pp. 140-155.

[2]   Y. Ito, T. Nakahigashi, N. Yoshimoto, Y. Ueda, N. Hamasaki and K Takada, “Transdermal Insulin Application System with Dissolving Microneedles,” Diabetes Technology and Therapeutics, Vol. 14, No. 10, 2012, pp. 891-899. doi:10.1089/dia.2012.0096

[3]   K. Fukushima, A. Ise, H. Morita, R. Hasegawa, Y. Ito, N. Sugioka and K. Takada, “Two-Layered Dissolving Microneedles for Percutaneous Delivery of Peptide/Protein Drugs in Rats,” Pharmaceutical Research, Vol. 28, No. 1, 2011, pp. 7-21. doi:10.1007/s11095-010-0097-7

[4]   Y. Ito, R. Hasegawa, K. Fukushima, N. Sugioka and K. Takada, “Self-Dissolving Microarray Chip as Percutaneous Delivery System of Protein Drug,” Biological and Pharmaceutical Bulletin, Vol. 33, No. 4, 2010, pp. 683690. doi:10.1248/bpb.33.683

[5]   Y. Ito, A. Saeki, K. Shiroyama, N. Sugioka and K. Takada, “Percutaneous Absorption of Interferon-α by Self-Dissolving Micropiles,” Journal of Drug Targeting, Vol. 16, No. 3, 2008, pp. 243-249. doi:10.1080/10611860801902575

[6]   H. S. Gill and M. R. Prausnitz, “Coated Microneedles for Transdermal Delivery,” Journal of Controlled Release, Vol. 117, No. 2, 2007, pp. 227-237. doi:10.1016/j.jconrel.2006.10.017

[7]   S. Henry, D. V. McAllis, M. G. Allen and M. R. Prausnitz, “Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery,” Journal of Pharmaceutical Sciences, Vol. 87, No. 8, 1998, pp. 922-925. doi:10.1021/js980042+

[8]   G. Levin, A. Gershonowitz, H. Sacks, M. Stern, A. Sherman, S. Rudaev, I. Zivin and M. Phillip, “Transdermal Delivery of Human Growth Hormone through RF-Microchannels,” Pharmaceutical Research, Vol. 22, No. 4, 2005, pp. 550-555. doi:10.1007/s11095-005-2498-6

[9]   B. Barry and A. Williams, “Penetration Enhancers,” Advanced Drug Delivery Reviews, Vol. 56, No. 5, 2004, pp. 603-618. doi:10.1016/j.addr.2003.10.025

[10]   G. Cevc, “Lipid Vesicles and Other Colloids as Drug Carriers on the Skin,” Advanced Drug Delivery, Vol. 56, No. 5, 2003, pp. 675-711. doi:10.1016/j.addr.2003.10.028

[11]   A. Doukas, “Transdermal Delivery with a Pressure Wave,” Advanced Drug Delivery, Vol. 56, No. 5, 2004, pp. 559579. doi:10.1016/j.addr.2003.10.031

[12]   S. Mitragotri and J. Kost, “Low-Frequency Sonophoresis: A Review,” Advanced Drug Delivery Reviews, Vol. 56, No. 5, 2004, pp. 589-601. doi:10.1016/j.addr.2003.10.024

[13]   V. Preat and R. Vanbever, “Skin Electroporation for Transdermal and Topical Delivery,” Advanced Drug Delivery Reviews, Vol. 56, No. 5, 2004, pp. 659-674. doi:10.1016/j.addr.2003.10.027

[14]   S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour and R. Kornowski. “Therapeutic Interventions for Enhancing Collateral Development by Administration of Growth Factors: Basic Principles: Early Results and Potential Hazards,” Cardiovascular Research, Vol. 4, No. 3, 2001, pp. 532542. doi:10.1016/S0008-6363(00)00217-0

[15]   S. Hashimoto, A. Hagino and Y. Amagai, “Fibroblast Growth Factor-Induced Decrease in the Phosphorylation of Nsp100 Mediated through a Calcium-Dependent Mechanism and Blocked by Lectin,” Cell Structure and Function, Vol. 15, No. 4, 1990, pp. 181-189. doi:10.1247/csf.15.181

[16]   M. Okumura, M. Yajima, T. Nishimura, H. Ikeda and T. Nishimori, “General Pharmacology of Recombinant Human Basic Fibroblast Growth Factor,” Arzneimittel Forschung, Vol. 46, No. 7, 1996, pp. 727-739.

[17]   P. Rieck, M. Assouline, M. Savoldelli, C. Hartmann, C. Jacob, Y. Pouliquen and Y. Courtois, “Recombinant Human Basic Fibroblast Growth Factor (Rh-bFGF) in Three Different Wound Models in Rabbits: Corneal Wound Healing Effect and Pharmacology,” Experimental Eye Research, Vol. 54, No. 6, 1992, pp. 987-998. doi:10.1016/0014-4835(92)90163-M

[18]   R. Westermann, C. Grothe and K. Unsicker. “Basic Fibroblast Growth Factor (bFGF), a Multifunctional Growth Factor for Neuroectodermal Cells,” Journal of Cell Science. Supplement, Vol. 13, 1990, pp. 97-117. doi:10.1242/jcs.1990.Supplement_13.10

[19]   Y. Akasaka, I. Ono, T. Kamiya, Y. Ishikawa, T. Kinoshita, S. Ishiguro, T. Yokoo and T. Ishii, “The Mechanisms Underlying Fibroblast Apoptosis Regulated by Growth Factors during Wound Healing,” The Journal of Pathology, Vol. 221, No. 3, 2010, pp. 285-299. doi:10.1002/path.2710

[20]   I. Ono, Y. Akasaka, R. Kikuchi, A. Sakemoto, T. Kamiya, T. Yamashita and K. Jimbow, “Basic Fibroblast Growth Factor Reduces Scar Formation in Acute Incisional Wounds,” Wound Repair and Regeneration, Vol. 15, No. 5, 2007, pp. 617-623. doi:10.1111/j.1524-475X.2007.00293.x

[21]   I. Ono, “The Effects of Basic Fibroblast Growth Factor (bFGF) on the Breaking Strength of Acute Incisional Wounds,” Journal of Dermatological Science, Vol. 29, No. 2, 2002, pp. 104-113. doi:10.1016/S0923-1811(02)00019-1

[22]   G. R. Grotendorst, “Chemoattractants and Growth Factors,” In: I. K. Cohen, R. F. Diegelmann, W. J. Lindblad, Eds., Wound Healing, W. B. Saunders Co., Philadelphia, 1992, pp. 237-246.

[23]   Y. Akasaka, I. Ono, A. Tominaga, Y. Ishikawa, K. Ito and T. Suzuki, “Basic Fibroblast Growth Factor in an Artificial Dermis Promotes Apoptosis and Inhibits Expression of Alpha-Smooth Muscle Actin, Leading to Reduction of Wound Contraction,” Wound Repair and Regeneration, Vol. 15, No. 3, 2007, pp. 378-389. doi:10.1111/j.1524-475X.2007.00240.x

[24]   Y. Akasaka, K. Ito, K. Fujita, K. Komiyama, I. Ono, Y. Ishikawa, Y. Akishima, H. Sato and T. Ishii, “Activated Caspase Expression and Apoptosis Increase in Keloids: Cytochrome C Release and Caspase-9 Activation during the Apoptosis of Keloid Fibroblast Lines,” Wound Repair and Regeneration, Vol. 13, No. 4, 2005, pp. 373-382. doi:10.1111/j.1067-1927.2005.130404.x

[25]   F. B. Anspach, H. Spille and U. Rinas, “Purification of Recombinant Human Basic Fibroblast Growth Factor: Stability of Selective Sorbents under Cleaning in Place Conditions,” Journal of Chromatography A, Vol. 711, No. 1, 1995, pp. 129-139. doi:10.1016/0021-9673(95)00102-S

[26]   S. Vemuri, I. Beylin, V. Sluzky, P. Stratton, G. Eberlein and Y. J. Wang, “The Stability of bFGF against Thermal Denaturation,” Journal of Pharmacy and Pharmacology, Vol. 46, No. 6, 1994, pp. 481-486. doi:10.1111/j.2042-7158.1994.tb03831.x

[27]   J. A. Wright and A. Huang, “Growth Factors in Mechanisms of Malignancy: Roles for TGF-β and FGF,” Histology and Histopathology, Vol. 11, 1996, pp. 521-536.

[28]   Y. Ishibashi, M. Furue, K. Kikuchi, M. Fujimoto, K. Takehara, S. Kawahara, M. Shirado, Y. Souma and M. Nindl, “Serum bFGF Concentrations Following Administration of KCB-1 in Patients with Intractable Skin Ulcers,” Journal Clinical Therapeutics and Medicines, Vol. 12, No. 10, 1996, pp. 2143-2158.

[29]   E. Tanaka, K. Ase, T. Okuda, M. Okumura and K. Nogimori, “Mechanism of Acceleration of Wound Healing by Basic Bibroblast Growth Factor in Genetically Diabetic Mice,” Biological and Pharmaceutical Bulletin, Vol. 19, No. 9, 1996, pp. 1141-1148. doi:10.1248/bpb.19.1141

[30]   G. Sun, X. Zhang, Y. Shen, R. Sebastain, L. E. Dickinson, K. Fox-Talbot, M. Reinblatt, C. Steenbergen, J. W. Harmon and S. Gerecht, “Dextran Hydrogel Scaffolds Enhance Angiogenic Responses and Promote Complete Skin Regeneration during Burn Wound Healing,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, No. 52, 2011, pp. 20976-20981. doi:10.1073/pnas.1115973108

[31]   Y. Xie, Z. Upton, S. Richards, S. C. Rizzi and I. David, “Leavesley, Hyaluronic Acid: Evaluation as a Potential Delivery Vehicle for Vitronectin: Growth Factor Complexes in Wound Healing Applications,” Journal of Controlled Release, Vol. 153, No. 3, 2011, pp. 225-232. doi:10.1016/j.jconrel.2011.03.021

 
 
Top